Companies › Visirna Therapeutics HK
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Gastroenterology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VSA003 RNA interference (RNAi) therapeutic targeting ANGPTL3 | ANGPTL3 | Phase 3 | Homozygous Familial Hypercholesterolemia (HoFH) | Dec 2027 |
| VSA006 siRNA targeting HSD17β13 mRNA to reduce HSD17β13 protein levels | HSD17B13 | Phase 2 | Nash | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06322628 | VSA006 | Phase 2 | Nash | Gastroenterology | Jan 2027 |
| NCT06712771 | VSA003 | Phase 3 | Homozygous Familial Hypercholesterolemia (HoFH) | Metabolic and endocrine | Dec 2027 |
Regeneron Pharmaceuticals Eddingpharm (Zhuhai) Verve Therapeutics Arrowhead Pharmaceuticals CRISPR Therapeutics
Myungmoon Pharma. Eddingpharm (Zhuhai) Rivus Pharmaceuticals Eccogene Guangdong Raynovent Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.